ACT Brief: Platform vs. Bespoke Technology, Patient and Site Experience Design, and AI-Driven ADC Development

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In the final segment of her video interview, Cheryl Kole, vice president of solution strategy and commercialization at Almac Clinical Technologies, offered a framework for deciding which emerging trial complexities should be built into core technology platforms and which are better managed as bespoke configurations.
• In part two of her series, Olga Elizarova, DDS, MPH, MBA, senior consultant behavioral science at S3 Connected Health, examined how poor patient and site experiences with confusing information, unreliable technology, and inefficient processes drive disengagement and dropout. Using mixed-method research combining quantitative and qualitative feedback, sponsors can identify sources of friction early and apply behavioral science to develop evidence-based solutions that improve trial performance.
• Daiichi Sankyo and Tempus AI announced a collaboration to apply multimodal AI and real-world data to ADC development, focusing on biomarker discovery and patient stratification. The partnership aims to generate response maps across diverse patient populations, enabling more precise cohort identification and more efficient clinical trial design in increasingly competitive oncology pipelines.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.